Your browser is no longer supported. Please, upgrade your browser.
AMGN Amgen Inc. daily Stock Chart
Amgen Inc.
IndexS&P 500 P/E16.05 EPS (ttm)10.26 Insider Own0.10% Shs Outstand736.00M Perf Week2.14%
Market Cap121.22B Forward P/E12.93 EPS next Y12.74 Insider Trans0.00% Shs Float734.84M Perf Month-0.63%
Income7.72B PEG2.47 EPS next Q3.00 Inst Own80.60% Short Float1.20% Perf Quarter9.21%
Sales22.99B P/S5.27 EPS this Y13.10% Inst Trans0.03% Short Ratio2.35 Perf Half Y5.33%
Book/sh40.59 P/B4.06 EPS next Y3.29% ROA10.10% Target Price185.23 Perf Year3.41%
Cash/sh51.75 P/C3.18 EPS next 5Y6.49% ROE25.90% 52W Range131.83 - 184.21 Perf YTD13.42%
Dividend4.60 P/FCF18.59 EPS past 5Y20.50% ROI13.00% 52W High-10.59% Beta1.28
Dividend %2.79% Quick Ratio3.90 Sales past 5Y8.10% Gross Margin81.90% 52W Low24.93% ATR2.46
Employees19200 Current Ratio4.10 Sales Q/Q7.70% Oper. Margin42.60% RSI (14)49.98 Volatility1.16% 1.21%
OptionableYes Debt/Eq1.16 EPS Q/Q10.50% Profit Margin33.60% Rel Volume0.94 Prev Close163.14
ShortableYes LT Debt/Eq1.01 EarningsApr 26 AMC Payout38.70% Avg Volume3.77M Price164.70
Recom2.40 SMA201.10% SMA50-2.93% SMA2002.51% Volume3,524,419 Change0.96%
Apr-05-17Downgrade Jefferies Buy → Hold
Mar-09-17Initiated UBS Neutral $185
Feb-01-17Upgrade BofA/Merrill Neutral → Buy
Dec-20-16Downgrade Credit Suisse Outperform → Neutral
Dec-13-16Initiated Oppenheimer Outperform
Nov-08-16Initiated Mizuho Buy $164
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-25-17 04:22PM  Amgen likely aiming to meet, not beat, first-quarter earnings expectations MarketWatch
03:46PM  Novartis, Amgen Divvy Global Marketing of New Migraine Drug
08:43AM  3 Stocks Could Double Their Dividends -- But Shouldn't Motley Fool
08:39AM  Why Earnings Season Could Be Great for Amgen (AMGN) Zacks
08:26AM  Earnings Preview: What To Expect From Amgen On Wednesday Forbes
06:50AM  Drug Stocks Q1 Earnings Releases on Apr 26: AMGN, GSK & More Zacks
Apr-24-17 04:30PM  Amgen Announces Expanded Commercial Collaboration With Novartis For Erenumab In Migraine PR Newswire
02:49PM  Biotech: 3 Things to Focus on as Biogen and Amgen Report
10:06AM  Is Pain Ahead for Healthcare ETFs After Weak JNJ Q1? Zacks
08:42AM  Better Buy: Amgen Inc. vs. Pfizer Motley Fool
Apr-23-17 06:55PM  Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector
02:03PM  Read This Before You Buy Biotech Stocks Motley Fool
10:25AM  Alphabet, Amazon, AT&T and Other Key Earnings Coming This Week 24/7 Wall St.
Apr-21-17 04:15PM  Amgen Trumps Regeneron, Sanofi In Cholesterol Drug Sales Investor's Business Daily
04:00PM  Amgen Announces Webcast Of 2017 First Quarter Financial Results PR Newswire
11:18AM  Amgen (AMGN) to Report Q1 Earnings: Will it Beat Again? Zacks
Apr-20-17 05:53PM  What to expect from biotech CNBC Videos
02:55PM  Celgene to expand in Cambridge, taking former Amgen space American City Business Journals
10:16AM  What's in Store for Biogen (BIIB) this Earnings Season? Zacks
09:31AM  Sanofi Genzyme hit with patent lawsuit over new eczema drug American City Business Journals
Apr-19-17 04:17PM  Is J&J's Pharma Sales Slowdown a Warning for Other Players? Zacks
Apr-18-17 04:00PM  Amgen Launches Neulasta® (pegfilgrastim) Onpro® NARRATIVES PR Newswire
09:30AM  The Zacks Analyst Blog Highlights: Alphabet, Amgen, Lowe's, Bristol-Myers and Priceline Zacks
Apr-17-17 05:43PM  Billion dollar drug bust CNBC Videos
04:43PM  Top Research Reports for Alphabet, Amgen & Lowe's Zacks
01:03PM  5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates Zacks
Apr-15-17 12:23AM  [$$] As Drug Prices Fall, These Stocks Could Rise
Apr-13-17 04:18PM  The Hot Stock: Alexion Pharmaceuticals Climbs 3.3%
Apr-12-17 03:46PM  Amgen's Offering a Money Back Guarantee for Repatha. Will It Be Enough? Motley Fool
12:51PM  How These Biotechs Could Save The Drug Sector In Q1 Or Not Investor's Business Daily
10:13AM  Don't Get Your Hopes Up For Biotech's Q1 Earnings
09:10AM  Short Sellers Back Off Major Biotechs 24/7 Wall St.
06:00AM  First Quarter Earnings Preview: Biotech Heavyweights Investopedia
Apr-11-17 03:03PM  3 Big Drugmakers Most Likely to Buy Incyte Motley Fool
08:08AM  The 3 Top Dividend Stocks in the Healthcare Sector Motley Fool
Apr-10-17 09:49AM  10 Reasons Amgen Could Be the World's Most Perfect Stock Motley Fool
03:40AM  Why Big Pharma Is Turning to Biological Drugs MarketWatch
Apr-09-17 04:16PM  Amgen Files Marketing Applications to Expand Xgeva's Use to US and EU MM Paitents
Apr-08-17 04:11PM  3 Big Biotech Stocks With Big-Time Catalysts Motley Fool
Apr-07-17 02:00PM  Earnings Preview: Biotechnology Looks Healthy
01:38PM  Analysts Release New Health Care Stock Ratings
01:34PM  Why Roche's New Drug Is Bad News For Biogen
Apr-06-17 03:31PM  Iceland's genetic goldmine, and the man behind it CNBC
03:30PM  Iceland: Genealogists' heaven CNBC Videos
01:08PM  Sanofi May Now Have Moved Past Its Most Challenging Period, Analyst Initiates At Buy Benzinga
08:03AM  This Is Why Radius Health Inc. Tumbled 8.6% in March Motley Fool
Apr-05-17 04:21PM  Amgen Payer Pushback Likely To Sting Amid Battle With Regeneron, Sanofi Investor's Business Daily
04:20PM  Citigroup, Wells Fargo Upgraded; Tenet A Buy; Teradyne PT Hiked Investor's Business Daily
12:06PM  Amgen Receives Hold Rating at Jefferies -- Jim Cramer Says It Could Be a Battleground
11:20AM  Amgen Files for Xgeva Label Expansion, To Include Myeloma Zacks
09:53AM  Cramer's Stop Trading: Amgen downgrade CNBC Videos
08:59AM  Biotech Stock Roundup: Acorda Down on Court Ruling, Patent Challenge for CELG Drug Zacks
04:00AM  Why Is Amgen (AMGN) Up 12.9% Since the Last Earnings Report? Zacks
Apr-04-17 11:12AM  As Biotech Roars Back, Amgen Remains Dirt Cheap
09:22AM  What's Next for Amgen's Repatha? Motley Fool
09:00AM  Amgen Submits Applications In The US And Europe To Expand Current Indication For XGEVA® (denosumab) To Include Patients With Multiple Myeloma PR Newswire
08:03AM  The No. 1 Dividend Grower For 2017 (From 50 Elite Finalists)
08:03AM  Amgen Offers A Money-Back Guarantee For Its Cholesterol Drug Repatha
Apr-03-17 03:10PM  Amgen will move 100 workers to San Francisco, Cambridge as part of restructuring at
11:00AM  Sarepta chief hands over CMO role to former Regeneron exec at
07:06AM  Kite Pharma Completes Filing for CAR-T Therapy with FDA
Apr-02-17 03:02PM  Healthcare Winners and Losers Following the AHCA's Failure at Motley Fool
Apr-01-17 11:42AM  Better Buy: Celgene Corporation vs. Amgen Inc. at Motley Fool
11:30AM  Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY (romosozumab) PR Newswire
Mar-31-17 03:36PM  FDA Grants Amgen Priority Review for Blincyto sBLA
10:36AM  Novartis Expects to Launch 5 Key Biosimilars by 2020
09:43AM  Can Vertex Keep Climbing? at
09:00AM  Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting PR Newswire
Mar-30-17 04:20PM  The 3 Best Cholesterol Drug Stocks to Buy in 2017 at Motley Fool
09:46AM  Amgen's Leukemia Drug Accepted for Priority Review by FDA
09:46AM  Amgen's Leukemia Drug Accepted for Priority Review by FDA at Investopedia
09:22AM  Amgen's Blincyto sBLA Secures FDA Priority Review at Investopedia
06:00AM  7 Dividends That Have Doubled Quickly at Motley Fool
Mar-29-17 04:07PM  FDA Grants Priority Review For Amgen's BLINCYTO® (blinatumomab) Supplemental Biologics License Application PR Newswire
04:03PM  Journal Of Clinical Oncology Publishes Data On BLINCYTO® (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia PR Newswire
03:42PM  3 Drugmakers With Boatloads of Cash to Spend at Motley Fool
11:55AM  Sanofi Genzyme files preemptive legal strike to protect eczema drug at
10:36AM  Cosentyx Enjoys Solid Demand as Psoriasis Therapy in Europe
09:06AM  Which Segments Will Drive the Most Growth for Novartiss Cosentyx?
09:06AM  Performance of Key Pharmaceuticals Products for GlaxoSmithKline
08:15AM  Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study
Mar-28-17 05:30PM  Amgen to move or cut nearly 500 jobs in Thousand Oaks at
09:00AM  Amgen Awards Three Golden Tickets for LabCentral Residency PR Newswire
08:57AM  Cousins (CUZ) Inks Lease with Amgen at Corporate Center
Mar-27-17 08:24PM  The 'Fearless Girl' Statue Isn't a Symbol, It Is an Advertisement
05:49PM  Amgen's Humira Biosimilar Approved in Europe
04:05PM  Could It Be Time to Buy US Domestic Moats?
10:30AM  Short Interest Pulls Back in Major Biotechs
09:08AM  Mercks Keytruda Saw Impressive Growth in 2016
08:42AM  5 Stocks With Ridiculously Fast-Growing Dividends at Motley Fool
Mar-24-17 04:41PM  Why You're Smart to Buy Jazz Pharmaceuticals plc at Motley Fool
03:11PM  Google life sciences spinoff soaks up huge space (video) at
01:44PM  Sanofi Could Acquire This Biotech, But Is $1 Billion Too Low?
11:27AM  Amgen's (AMGN) Humira Biosimilar Receives Approval in EU
09:30AM  The Zacks Analyst Blog Highlights: Berkshire Hathaway, Amgen, Walgreens Boots Alliance, General Electric and Carnival
05:24AM  Amgen Secures EU Approval for Anti-Inflammatory Drug at Investopedia
Mar-23-17 04:00PM  European Commission Approves AMGEVITA (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases PR Newswire
03:40PM  Stock Research Reports for Amgen, Berkshire & Walgreens
02:07PM  Regeneron, Sanofi Look To Crush Amgen, And Rivals Say They Can
10:57AM  Biotechs Back in the Doghouse After Failed Rally at Investopedia
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for the prevention of skeletal-related events; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Erenumab for the prevention of chronic migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; AMJEVITA to treat psoriatic arthritis and polyarticular juvenile idiopathic arthritis, as well as ankylosing spondylitis and moderate-to-severe rheumatoid arthritis; ABP 215 for biosimilar candidates; and ABP 980 to treat human epidermal growth factor receptor 2-positive early breast cancer. The company's other marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products for use to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de Carbonnel FrancoisDirectorSep 09Option Exercise71.645,000358,20021,171Sep 13 06:21 PM
Such Annette LouiseVP, Finance and CAOAug 02Sale174.593,000523,7587,183Aug 03 08:14 PM
Balachandran MadhavanEVP, OperationsMay 04Sale154.1230,0004,623,62455,996May 05 08:16 PM
BALTIMORE DAVIDDirectorApr 29Sale157.213,312520,68432,350May 03 07:12 PM